Natural products known to have efficacy for gliobalstoma will be incorporated into monodisperse silica nanoaprticles and silane analogs. Established human cell line LN-229 will be treated with different doses of these nanoparticle drugs and the expression levels of key oncogenes will be monitored to determine if growth and proliferation of these cells is arrested. Factors such as time of treatment, dosage, and nanoaprticle size will be studied to determine the optimum conditions. Additionally the SN-K-AS T-cell immune cells will be treated with these drugs to determine their efficacies for promoting the activity of the immune cells. The effect of the nanoscale drugs on the combined population of LN-229 gliobalstoma and SN-K-As T-cells will be evlauted to understand their efficacies for stimulating the immue system to combat gliobalstoma. These in vitro studies are useful models for determining the therapeutic efficacies of nanoscale drugs for gliblastoma treatment.